Authors
Latest:
Navigating mCRC: Treatment Options in the Third-Line SettingPanelists discuss their preferred treatment options for patients in the third-line setting of metastatic colorectal cancer (mCRC), focusing on regorafenib, trifluridine-tipiracil plus bevacizumab, and fruquintinib, and share insights on how patient and disease-specific factors influence the selection of the most appropriate regimen for each clinical scenario.
Latest:
Dr Tantravahi on the Efficacy of Selinexor Plus Ruxolitinib in JAK Inhibitor–Naive MyelofibrosisSrinivas K. Tantravahi, MBBS, MRCP, discusses the preliminary efficacy of selinexor in combination with ruxolitinib in patients with JAK inhibitor–naive myelofibrosis, as seen in the phase 1 XPORT-MF-034 trial.
Latest:
Dr. McGuinness on Mitigating GI Toxicities With PI3K Inhibitors in PI3K-Mutated Breast CancerJulia E. McGuinness, MD, discusses combating gastrointestinal toxicities in PI3K-mutated breast cancer.
Latest:
Novel Therapies for R/R Follicular LymphomaA panel of hematologists/oncologists remark on the transformations occurring in relapsed/refractory follicular lymphoma as newer, novel therapies continue to emerge.
Latest:
Operational Processes and ChallengesMark Robson, MD; John Henson, MD; Ashley Ross, MD, PhD; and Dana Farengo Clark, MS, LCGC, discuss operational processes and techniques for counseling patients about germline testing.
Latest:
Acimtamig Plus Allogeneic Natural Killer Cells Under Phase 2 Evaluation in R/R Hodgkin Lymphoma and CD30+ PTCLFollowing promising preclincial findings, acimtamig plus allogenic natural killer cells will be examined for the treatment of patients with relapsed/refractory Hodgkin lymphoma and CD30-positive peripheral T-cell lymphoma.
Latest:
Dr. Iams on the Rationale of Targeting LAG-3 in Advanced NSCLCWade T. Iams, MD, discusses the rationale of targeting the LAG-3 pathway in patients with advanced non–small cell lung cancer.
Latest:
Dr Banerjee on Future Hopes For Bispecific Antibody Therapy in MyelomaRahul Banerjee, MD, FACP, discusses his hopes for the future of bispecific antibody therapy for patients with multiple myeloma.
Latest:
Dr. Walters on the Drawbacks of Transfusion Dependence in Pediatric Beta-ThalassemiaMark Walters, MD, discusses the limitations of standard blood transfusions in pediatric patients with transfusion-dependent beta-thalassemia.
Latest:
Dr Schiff on PFS and OS Data With Temozolomide Plus Radiation in Grade II GliomaDavid Schiff, MD, discusses PFS and OS data for radiation with or without temozolomide in patients with grade II glioma.
Latest:
Dr Zhang on the Rationale for Investigating Sintilimab/Axitinib in FH-Deficient RCCXingming Zhang, MD, discusses the rationale for investigating the combination of sintilimab and axitinib in patients with advanced fumarate hydratase-deficient renal cell carcinoma in a phase 2 trial.
Latest:
PD-L1 Status Stratifies Immunotherapy Treatment in NSCLCData from completed studies evaluating immunotherapy in lung cancer alone or in combination with chemotherapy show that a breakdown of populations by PD-L1 status and additional considerations such as toxicity profiles should guide treatment decisions.
Latest:
Dr. Burnham on Correlations Between Race and HER2 Positivity in Prostate CancerLeanne Burnham, PhD, discusses the correlation between HER2 positivity and race in patients with prostate cancer.
Latest:
Dr Oveisi on the Importance of Patient Counseling Prior to CAR T-Cell Therapy in MyelomaDavid R. Oveisi, MD, discusses the importance of clear communication with patients prior to administering CAR T-cell therapy for multiple myeloma.
Latest:
Education Is a Personal MissionSantosh Saraf, MD, changed his major 3 times as an undergrad at Penn State University, bouncing from premed to mathematics to marine biology before settling back into medicine.
Latest:
Dr. Korde on Updated Findings From the Cassiopeia Trial in Multiple MyelomaNeha S. Korde, MD, hematologist, Memorial Sloan Kettering Cancer Center, discusses key updates to the phase 3 Cassiopeia study (NCT02541383) in multiple myeloma.
Latest:
Dr Yuan on the Evolution of Radiation Therapy Approaches in Breast CancerYuan Yuan, MD, PhD, discusses radiation therapy approaches across various of breast cancer subtypes.
Latest:
Final Thoughts on EHA 2024 Data for Lower-Risk MDSKey opinion leaders summarize their main insights and key takeaways from the EHA 2024 conference regarding advances in lower-risk myelodysplastic syndrome treatment.
Latest:
Real-World (RW) Systemic Treatment Patterns in US Patients (PTS) With Hepatocellular Carcinoma (HCC) 2020–2022Stephen Chan, MD, presents real-world data from a systemic review of treatment patterns in the United States of patients with hepatocellular carcinoma from 2020 to 2022.
Latest:
Key Takeaways From DiscussionPhysicians share key takeaways from the discussion on diagnosis and treatment of immune thrombocytopenia.
Latest:
Key Takeaways For Treating Patients Diagnosed With CholangiocarcinomaProvider and patient perspectives on why patient education about FGFRi treatment-associated adverse events and how to manage them are is essential in helping patients maintain a good quality of life and stay on treatment.
Latest:
Dr Schlechter on TAC01-HER2 Therapy in HER2+ Solid TumorsBenjamin L. Schlechter, MD, discusses the future implications of TAC01-HER2 therapy in patients with HER2-positive solid tumors.
Latest:
Holistic and Multidisciplinary Approaches to Multiple Myeloma ManagementClosing out their program on multiple myeloma, expert panelists consider the role of holistic and multidisciplinary care when managing patients within the current paradigm.
Latest:
Overview of PERSEUS, IsKia, and GMMG-HD7Douglas Sborov, MD, discusses a brief overview of key clinical trials, including PERSEUS, IsKia, and GMMG-HD7, highlighting their implications for the treatment of patients with NDMM.
Latest:
What is on the Horizon for Adjuvant Therapy in Early-Stage Breast Cancer?Expert medical oncologists take a step into the future and discuss developments within the adjuvant setting of early-stage breast cancer they are most excited about.
Latest:
Future Management of Uveal MelanomaThe next steps in research investigating best practices using novel therapies such as tebentafusp as treatment for uveal melanoma.
Latest:
Dr. Parker Discusses the Importance of Optimizing Treatment in Multiple MyelomaTerri Parker, MD, discusses considerations to optimize treatment in multiple myeloma.
Latest:
Novel Therapies Under Study for Triple-Class Refractory Multiple MyelomaNovel therapies in clinical development to improve outcomes for patients with triple-class refractory multiple myeloma.
Latest:
Dr. Goswami's Oncology Journey: Patient-centric Science and Mentorship StoriesSangeeta Goswami, MD, PhD, discusses her career focused in genitourinary cancers, with a focus on patient-centric science and shares mentorship stories along the way.
.jpg?fit=crop&auto=format)
